{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:06:36Z","timestamp":1789344396588,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die transurethrale Resektion von Blasengewebe (TUR-B) ist f\u00fcr die Diagnostik und Therapie bei Blasentumoren indiziert. Diese werden fragmentiert mittels diathermaler Schlinge abgetragen. Der Wundgrund wird zur Blutstillung koaguliert. Zu achten ist auf eine ausreichende Schnitttiefe, sodass die Detrusormuskulatur erfasst ist. Postoperativ kann zur Rezidivprophylaxe eine intravesikale Single-shot-Chemotherapie verabreicht werden. Methoden zur verbesserten Tumorvisualisation (insbesondere photodynamische Diagnostik) helfen, besonders bei multilokul\u00e4rem Befund oder Carcinoma in situ (CIS) bessere Detektionsraten zu erreichen sowie das Rezidiv- und Progressionsrisiko zu senken. In Abh\u00e4ngigkeit von der Histologie ergibt sich das weitere Vorgehen: bei nicht muskelinvasivem Blasenkarzinom Nachsorge, adjuvante Instillationstherapie mittels Chemotherapie oder Bacillus Calmette-Gu\u00e9rin (BCG), die Nachresektion (\u201esecond look TUR-B\u201c), die Fr\u00fchzystektomie oder bei muskelinvasivem Blasenkarzinom die Zystektomie oder (onkologisch nachrangig) die trimodale Therapie mit erneuter TUR\u2011B, Radiotherapie und Chemotherapie. M\u00f6gliche Komplikationen im Rahmen der TUR\u2011B sind v.\u202fa. Nachblutung mit Blasentamponade, extra- oder intraperitoneale Blasenperforation oder Infektionen des Urogenitaltrakts.<\/jats:p>","DOI":"10.1007\/s00120-021-01741-z","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:04:44Z","timestamp":1641294284000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Transurethrale Resektion von Blasentumoren (TUR-B)","Transurethral resection of bladder tumors (TURBT)"],"prefix":"10.1007","volume":"61","author":[{"given":"D.","family":"Oswald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pallauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. R. W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Netsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lehrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Miernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Sch\u00f6b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D.","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lusuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"5","key":"1741_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay\u00a0J, Soerjomataram\u00a0I, Dikshit\u00a0R et\u00a0al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"2","key":"1741_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger\u00a0M, Catto\u00a0JWF, Dalbagni\u00a0G et\u00a0al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033","journal-title":"Eur Urol"},{"issue":"5","key":"1741_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Comp\u00e9rat\u00a0EM et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur Urol 76(5):639\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"issue":"1","key":"1741_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","volume":"19","author":"M Deuker","year":"2021","unstructured":"Deuker\u00a0M, Martin\u00a0T, Stolzenbach\u00a0F et al (2021) Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer 19(1):60\u201368.e1. https:\/\/doi.org\/10.1016\/j.clgc.2020.07.011","journal-title":"Clin Genitourin Cancer"},{"key":"1741_CR5","volume-title":"TNM classification of malignant tumors","author":"M Gospodarowicz","year":"2017","unstructured":"Gospodarowicz\u00a0M, Brierley\u00a0J, Wittekind\u00a0C (2017) TNM classification of malignant tumors, 8.\u00a0Aufl. Wiley-Blackwell, New York, USA","edition":"8"},{"key":"1741_CR6","unstructured":"Eble\u00a0J, Sauter\u00a0G, Epstein\u00a0J, Sesterhenn\u00a0I (2016) Pathology and genetics of tumours of the urinary system and male genital organs, 3.\u00a0Aufl. WHO classification of tumours. Lyon, France"},{"key":"1741_CR7","doi-asserted-by":"crossref","unstructured":"Moch\u00a0H, Humphrey\u00a0P, Ulbright\u00a0T, Reuter\u00a0V (2016) WHO classification of tumours of the urinary system and male genital organs, 4.\u00a0Aufl. Lyon, France","DOI":"10.1016\/j.eururo.2016.02.028"},{"issue":"5","key":"1741_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi\u00a0M, Collette\u00a0L, Kurth\u00a0K et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41(5):523\u2013531. https:\/\/doi.org\/10.1016\/S0302-2838(02)00068-4","journal-title":"Eur Urol"},{"issue":"4","key":"1741_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ, Rodr\u00edguez\u00a0O, Hern\u00e1ndez\u00a0V et al (2021) European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79(4):480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"key":"1741_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055","author":"JA Witjes","year":"2020","unstructured":"Witjes\u00a0JA, Bruins\u00a0HM, Cathomas\u00a0R et al (2020) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"issue":"6","key":"1741_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch\u00a0MGK, Foerster\u00a0B, Catto\u00a0JWF et al (2018) Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73(6):925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","journal-title":"Eur Urol"},{"issue":"4","key":"1741_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","volume":"4","author":"A Naselli","year":"2018","unstructured":"Naselli\u00a0A, Hurle\u00a0R, Paparella\u00a0S et al (2018) Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4(4):558\u2013567. https:\/\/doi.org\/10.1016\/j.euf.2016.12.011","journal-title":"Eur Urol Focus"},{"issue":"9","key":"1741_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00120-016-0196-0","volume":"55","author":"M Retz","year":"2016","unstructured":"Retz\u00a0M, Maisch\u00a0P, Gschwend\u00a0JE (2016) S3-Leitlinie Harnblasenkarzinom. Urologe 55(9):1188\u20131191. https:\/\/doi.org\/10.1007\/s00120-016-0196-0","journal-title":"Urologe"},{"issue":"5","key":"1741_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bju.13102","volume":"116","author":"S Baltac\u0131","year":"2015","unstructured":"Baltac\u0131\u00a0S, Bozlu\u00a0M, Y\u0131ld\u0131r\u0131m\u00a0A et al (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Gu\u00e9rin. BJU Int 116(5):721\u2013726. https:\/\/doi.org\/10.1111\/bju.13102","journal-title":"BJU Int"},{"issue":"6","key":"1741_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2005.01.017","volume":"47","author":"M Lodde","year":"2005","unstructured":"Lodde\u00a0M, Palermo\u00a0S, Comploj\u00a0E et\u00a0al (2005) Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 47(6):773\u2013779. https:\/\/doi.org\/10.1016\/j.eururo.2005.01.017","journal-title":"Eur Urol"},{"key":"1741_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-53981-1","volume-title":"Endoskopische Urologie \u2013 Atlas und Lehrbuch","author":"R Hofmann","year":"2018","unstructured":"Hofmann\u00a0R (2018) Endoskopische Urologie \u2013 Atlas und Lehrbuch"},{"key":"1741_CR17","volume-title":"Hinman\u2019s Atlas of urologic surgery","author":"JJ Smith","year":"2018","unstructured":"Smith\u00a0JJ, Howards\u00a0S, Preminger\u00a0G, Dmochowski\u00a0R (2018) Hinman\u2019s Atlas of urologic surgery"},{"key":"1741_CR18","volume-title":"Praxis der Urologie","author":"D Jocham","year":"2020","unstructured":"Jocham\u00a0D, Miller\u00a0K, Burger\u00a0M, Schrader\u00a0M (2020) Praxis der Urologie Bd. 2"},{"issue":"3","key":"1741_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0APM, Oosterlinck\u00a0W et\u00a0al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596\u00a0patients from seven EORTC trials. Eur Urol 49(3):466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"issue":"1","key":"1741_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12885-020-6620-2","volume":"20","author":"MC Hupe","year":"2020","unstructured":"Hupe\u00a0MC, Dormayer\u00a0L, Ozimek\u00a0T et\u00a0al (2020) Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer. BMC Cancer 20(1):140. https:\/\/doi.org\/10.1186\/s12885-020-6620-2","journal-title":"BMC Cancer"},{"issue":"6","key":"1741_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.euf.2016.12.004","volume":"3","author":"MW Kramer","year":"2017","unstructured":"Kramer\u00a0MW, Altieri\u00a0V, Hurle\u00a0R et al (2017) Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus 3(6):567\u2013576. https:\/\/doi.org\/10.1016\/j.euf.2016.12.004","journal-title":"Eur Urol Focus"},{"issue":"6","key":"1741_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00120-018-0625-3","volume":"57","author":"JP Struck","year":"2018","unstructured":"Struck\u00a0JP, Karl\u00a0A, Schwentner\u00a0C, Herrmann\u00a0TRW, Kramer\u00a0MW (2018) En bloc resection and vaporization techniques for the treatment of bladder cancer. Urologe\u00a0A 57(6):665\u2013672. https:\/\/doi.org\/10.1007\/s00120-018-0625-3","journal-title":"Urologe A"},{"issue":"2","key":"1741_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MOU.0000000000000377","volume":"27","author":"TRW Herrmann","year":"2017","unstructured":"Herrmann\u00a0TRW, Wolters\u00a0M, Kramer\u00a0MW (2017) Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype. Curr Opin Urol 27(2):182\u2013190. https:\/\/doi.org\/10.1097\/MOU.0000000000000377","journal-title":"Curr Opin Urol"},{"issue":"8","key":"1741_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.urolonc.2014.04.005","volume":"32","author":"Y Neuzillet","year":"2014","unstructured":"Neuzillet\u00a0Y, Methorst\u00a0C, Schneider\u00a0M et al (2014) Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. Urol Oncol 32(8):1135\u20131140. https:\/\/doi.org\/10.1016\/j.urolonc.2014.04.005","journal-title":"Urol Oncol"},{"issue":"4","key":"1741_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","volume":"57","author":"ROP Draga","year":"2010","unstructured":"Draga\u00a0ROP, Grimbergen\u00a0MCM, Kok\u00a0ET, Jonges\u00a0TN, van Swol\u00a0CFP, Bosch\u00a0JLHR (2010) Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C intravesical therapy. Eur Urol 57(4):655\u2013660. https:\/\/doi.org\/10.1016\/j.eururo.2009.09.037","journal-title":"Eur Urol"},{"issue":"6","key":"1741_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","volume":"105","author":"ER Ray","year":"2010","unstructured":"Ray\u00a0ER, Chatterton\u00a0K, Khan\u00a0MS et al (2010) Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Gu\u00e9rin. BJU Int 105(6):789\u2013794. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08839.x","journal-title":"BJU Int"},{"issue":"5","key":"1741_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00345-016-1927-y","volume":"35","author":"AI Rolevich","year":"2017","unstructured":"Rolevich\u00a0AI, Zhegalik\u00a0AG, Mokhort\u00a0AA et al (2017) Results of a\u00a0prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. World J Urol 35(5):745\u2013752. https:\/\/doi.org\/10.1007\/s00345-016-1927-y","journal-title":"World J Urol"},{"issue":"3 Pt 1","key":"1741_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.juro.2016.10.061","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou\u00a0R, Selph\u00a0S, Buckley\u00a0DI et al (2017) Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis. J\u00a0Urol 197(3 Pt 1):548\u2013558. https:\/\/doi.org\/10.1016\/j.juro.2016.10.061","journal-title":"J Urol"},{"key":"1741_CR29","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.1038\/srep10905","volume":"5","author":"Z Ye","year":"2015","unstructured":"Ye\u00a0Z, Hu\u00a0J, Song\u00a0X et al (2015) A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: a prospective, randomized and multi-center study. Sci Rep 5:10905. https:\/\/doi.org\/10.1038\/srep10905","journal-title":"Sci Rep"},{"issue":"2","key":"1741_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/21681805.2017.1295101","volume":"51","author":"D Drejer","year":"2017","unstructured":"Drejer\u00a0D, B\u00e9ji\u00a0S, Munk Nielsen\u00a0A, H\u00f8yer\u00a0S, Wrist Lam\u00a0G, Jensen\u00a0JB (2017) Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa\u20117 study. Scand J Urol 51(2):120\u2013123. https:\/\/doi.org\/10.1080\/21681805.2017.1295101","journal-title":"Scand J Urol"},{"issue":"2","key":"1741_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4111\/icu.2018.59.2.98","volume":"59","author":"SB Kim","year":"2018","unstructured":"Kim\u00a0SB, Yoon\u00a0SG, Tae\u00a0J et al (2018) Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy. Investig Clin Urol 59(2):98\u2013105. https:\/\/doi.org\/10.4111\/icu.2018.59.2.98","journal-title":"Investig Clin Urol"},{"issue":"11","key":"1741_CR32","doi-asserted-by":"publisher","first-page":"E680","DOI":"10.1111\/j.1464-410X.2012.11500.x","volume":"110","author":"C Zheng","year":"2012","unstructured":"Zheng\u00a0C, Lv\u00a0Y, Zhong\u00a0Q, Wang\u00a0R, Jiang\u00a0Q (2012) Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 110(11):E680\u20137. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11500.x","journal-title":"BJU Int"},{"issue":"3","key":"1741_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"S Naito","year":"2016","unstructured":"Naito\u00a0S, Algaba\u00a0F, Babjuk\u00a0M et al (2016) The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1\u2011year results. Eur Urol 70(3):506\u2013515. https:\/\/doi.org\/10.1016\/j.eururo.2016.03.053","journal-title":"Eur Urol"},{"issue":"5","key":"1741_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1089\/end.2015.0687","volume":"30","author":"GM Kamphuis","year":"2016","unstructured":"Kamphuis\u00a0GM, de Bruin\u00a0DM, Brandt\u00a0MJ et\u00a0al (2016) Comparing image perception of bladder tumors in four different Storz professional image enhancement system modalities using the \u00edSPIES app. J\u00a0Endourol 30(5):602\u2013608. https:\/\/doi.org\/10.1089\/end.2015.0687","journal-title":"J Endourol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01741-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01741-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01741-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:04:13Z","timestamp":1642417453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01741-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1741"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01741-z","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"29 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.\u00a0Oswald<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Assistenzarzt f\u00fcr Urologie und Andrologie, Universit\u00e4tsklinik Salzburg. Mitgliedschaften: \u00d6GU, EAU. <b>M.\u00a0Pallauf<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Assistenzarzt f\u00fcr Urologie, Universit\u00e4tsklinik f\u00fcr Urologie und Andrologie, Uniklinikum Salzburg. Mitgliedschaften: \u00d6sterreichische Gesellschaft f\u00fcr Urologie und Andrologie (Vorsitzender der Assistenz\u00e4rzte 2018\u20132021). <b>T.\u00a0R.\u00a0W.\u00a0Herrmann<\/b> gibt finanzielle Interessen an: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Reisestipendien: SIU, ESUT, EAU, ESU, Konsultant\/Honorare: Karl Storz, Honorare: Boston Scientific. Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Karl Storz Fortbildung. Nichtfinanzielle Interessen: Klinikdirektor und Chefarzt, Urologische Klinik der Spital Thurgau AG. <b>C.\u00a0Netsch<\/b> gibt finanzielle Interessen an: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Richard Wolf (Honorar), Lisa Laser (Honorar). Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Lisa Laser (Proctor), Richard Wolf (Proctor). Nichtfinanzielle Interessen: Angestellter Arzt, Oberarzt, AK Barmbek, Urologie, Hamburg. Mitgliedschaften: DGU, EAU, Arbeitskreis Endourologie, Endourological Society, GesRU, Deutsche Kontinenz Gesellschaft.<b> B.\u00a0Becker<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Oberarzt Urologie, Asklepios Klinik Barmbek. Mitgliedschaft: Arbeitskreis Endourologie der DGU. <b>K.\u00a0Lehrich<\/b> gibt finanzielle Interessen an: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Honorare: Lumenis Ltd., Boston Scientific, Janssen. Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Coloplast: Berater Laseranwendung, Lumenis: Hospitationen. Nichtfinanzielle Interessen: Angestellte \u00c4rztin, Klinik Vivantes AVK, praktizierende niedergelassene \u00c4rztin. Mitgliedschaften: Berufsverband der Urologen, Arbeitskreis Endourologie, DGU, Endourology Society, DGHO, BUG, EAU. <b>A.\u00a0Miernik<\/b> gibt finanzielle Interessen an: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Bundesministerium f\u00fcr Bildung und Forschung (BMBF), DE: Forschungsmittel; Europ\u00e4ische Kommission, LUX: Forschungsmittel. Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Reisesponsoring: Deutsche Gesellschaft f\u00fcr Urologie, DE; Europ\u00e4ische Gesellschaft f\u00fcr Urologie, NL; Procept Biorobotics, USA. Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Autor: Verlag Walter de Gruyter, DE; Springer Verlag, DE. Autor, Referent: Richard Wolf GmbH, DE, Berater A: KLS Martin, Tuttlingen; Berater: Dornier MedTech Europe GmbH, DE; B. Braun New Ventures GmbH, DE; Medi-Tate Ltd., Israel, A. Reviewer: Ludwig Boltzmann Gesellschaft. Patente, Gesch\u00e4ftsanteile, Aktien o.\u202f\u00c4. an einer im Medizinbereich aktiven Firma: Purenum GmbH, Deutschland (Patent). Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrender Oberarzt Personaloberarzt, Klinik f\u00fcr Urologie, Sektion f\u00fcr Urotechnologie, Universit\u00e4tsklinikum Freiburg. Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie, Europ\u00e4ische Gesellschaft f\u00fcr Urologie, Endourological Society, Americal Urological Association, Deutsche Gesellschaft f\u00fcr Extrakorporale Sto\u00dfwellentherapie. <b>D.\u00a0S.\u00a0Sch\u00f6b<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Angestellter Urologe, Uniklinikum Freiburg. Mitgliedschaften: DGU, EAU, GESRU, Marburger Bund. <b>K.\u00a0D.\u00a0Sievert<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Leitender Arzt Neurourologie, Klinikum Lippe, R\u00f6ntgenstra\u00dfe\u00a018, 32756 Detmold. <b>A.\u00a0J.\u00a0Gross<\/b> gibt finanzielle Interessen an: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Fa. Cook Medical. Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: OP-Seminare: Cook Medical. Nichtfinanzielle Interessen: Chefarzt, Klinik f\u00fcr Urologie, Asklepios Klinik Barmbek. <b>J.\u00a0Westphal<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Chefarzt der Klinik f\u00fcr Urologie, Kinderurologie und Urogyn\u00e4kologie, Krankenhaus Maria Hilf der Alexianer Krefeld GmbH. Mitgliedschaften: DGU, BvDU, AK Endourologie der DGU, AG der Leitenden Krankenhaus\u00e4rzte der DGU, Vorsitzender des AK Angestellte \u00c4rzte des BvDU. <b>L.\u00a0Lusuardi<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Angestellter Urologe, Universit\u00e4tsklinik Urologie, PMU Salzburg, SALK. <b>S.\u00a0Deininger<\/b> gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Beruflicher Werdegang: Seit November 2021: Ober\u00e4rztin an der Universit\u00e4tsklinik f\u00fcr Urologie und Andrologie, Landeskrankenhaus Salzburg; Mai 2021: Erwerb \u00d6\u00c4K-Diplom Palliativmedizin; Seit November 2019: Fach\u00e4rztin an der Universit\u00e4tsklinik f\u00fcr Urologie und Andrologie, Landeskrankenhaus Salzburg; November 2019: Erwerb der Zusatzbezeichnung medikament\u00f6se Tumortherapie, Bayerische Landes\u00e4rztekammer; Oktober 2019: Erwerb der Facharztbezeichnung f\u00fcr Urologie, Bayerische Landes\u00e4rztekammer; April 2018 bis Oktober 2019: Assistenz\u00e4rztin in der Abteilung f\u00fcr Urologie, Klinikum Traunstein, Chef\u00e4rzte Dr. J. Schuhbeck, Dr. P. Weidlich, Prof. Dr. D. Zaak; Juli 2014 bis M\u00e4rz 2018 Assistenz\u00e4rztin an der Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum T\u00fcbingen, Chefarzt Prof. Dr. A. Stenzl. Mitgliedschaften: \u00d6sterreichische Gesellschaft f\u00fcr Urologie, European Association of Urology, Nepali Rotzn\u00e4schen e.\u202fV., Die \u00c4rzte f\u00fcr Afrika e.\u202fV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}